MON-494 - Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients with Classic Congenital Adrenal Hyperplasia

Rapid and Poster Presenter(s)

• 

  Laura Curd, MS (she/her/hers)

  Director, Pharmacometrics
  Crinetics Pharmaceuticals, Inc.
  San Diego, CA, United States

Co-Author(s)

• XW

  Xiaoli Wang, PhD

  Crinetics Pharmaceuticals
  San Diego, California, United States
• AW

  Adam Worob, PhD

  A2-Ai
  Ann Arbor, Michigan, United States
• DR

  Davide Romeres, PhD

  A2-Ai
  Ann Arbor, Michigan, United States
• RC

  Ryan L. Crass, PharmD

  A2-Ai
  Ann Arbor, Michigan, United States
• AA

  Alejandro Ayala, MD

  Crinetics Pharmaceuticals
  San Diego, California, United States
• CL

  Carl LaCerte, MS

  Crinetics Pharmaceuticals
  San Diego, California, United States